GSK Agrees to Settle Flonase Antitrust Actions for $195 Mil.

Drugmaker GlaxoSmithKline has agreed to settle with plaintiffs for a total of $195 million over allegations that it monopolized the market for its nasal spray Flonase.

This article requires free registration

This article requires free registration to The Legal Intelligencer. Please sign in or register to read the full text.